SUBSCRIBERS
China cancer patients turn to unapproved drugs on grey market
Published Mon, Dec 26, 2016 · 09:50 PM
Shanghai
WHEN her father's lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly US$3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.
Ms Yin, like many families in China, turned to the increasingly popular, unregulated market of online pharmacies, agents and peer groups for drugs.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO